Skip to Main Content
For healthcare professionals

A Phase I, non-randomized, open-label, multi-center dose escalation trial of a DLL3/CD3 T-cell engager (obrixtamig) combined with ezabenlimab in patients with small cell lung carcinoma and other neuroendocrine neoplasms expressing DLL3 (NCT05879978)1,2

DLL3/CD3 T-cell engager: NCT05879978 (1438-0002)
DLL3/CD3 T-cell engager: NCT05879978 (1438-0002)

AUC, area under the curve; Cmax, peak serum concentration; CD3, cluster of differentiation 3; CNS, central nervous system; DLL3, delta-like canonical Notch ligand 3; DLT, dose-limiting toxicity; IHC, immunohistochemistry; LCNEC-L, large cell neuroendocrine carcinoma of the lung; MTD, maximum tolerated dose; NEC, neuroendocrine carcinoma; OR, objective response; RECIST, Response Evaluation Criteria In Solid Tumours; SCLC, small cell lung cancer.

References

  1. ClinicalTrials.gov. NCT05879978. https://www.clinicaltrials.gov/study/NCT05879978 (Accessed: August 2025).

  2. Mazières J, et al. ESMO 2023. Poster 2028TiP.